Your input will help us improve your experience.
Your input will help us improve your experience.You can close this popup to continue using the website or choose an option below to register in or login.
Already have an account? Sign in
Sign up free to keep exploring.
We use Necessary cookies to make our website work. We’d also like to set optional Functional cookies to gather anonymous site visitation data and Advertising cookies to help us understand which content our visitors value the most. By enabling these cookies, you can help us provide a better website for you. These will be set only if you accept.More information about the cookies we use can be found here Cookies Policy
Thanks for visiting TopUniversities.com today! So that we can show you the most relevant information, please select the option that most closely relates to you.
Stanford GSB Strips Convicted Insider Trader of MBA: MBA News
By QS Contributor
Updated UpdatedFormer S.A.C. Capital Advisors trader Mathew Martoma has had his MBA revoked by the Stanford Graduate School of Business (Stanford GSB) after it came to light that he had previously been expelled from Harvard Law School for faking his grades. This comes a month after a highly-publicized conviction for insider trading.
The Stanford GSB admissions process requires any previous academic disciplinary action to be reported. Martoma neglected to mention that he had been expelled from Harvard in 1999 when enrolling at Stanford GSB in 2001. The revelation of such an expulsion would have been a “serious impediment” to his being admitted into the school, a Stanford source revealed to The New York Times.
Loss of MBA follows insider trading conviction for S.A.C. Capital Advisors trader Mathew Martoma
Mathew Martoma was convicted of insider trading in early February, having helped to earn S.A.C. Capital Advisors US$250 million through deals based on secret knowledge of trials of a new Alzheimer’s drug, sponsored by drug makers Elan and Wyeth.
The then Stanford GSB graduate learned the secrets from Sidney Gilman, formerly a professor of neurology at the University of Michigan, who he paid US$1 million over several years for consultations, The Telegraph reports. After finding out the results of clinical trials, S.A.C. Capital Advisors sold their shares in the drug makers, and built a short position from which the company made a huge profit after the public announcement of the test results.
Mathew Martoma will be sentenced in June. He faces up to a decade behind bars for his participation in the biggest insider trading scheme in the history of the US, with S.A.C. Capital Advisors pleading guilty in November for encouraging such tactics for over a decade. The firm has agreed to pay US$1.8 billion to settle the charges.
Image: Spencer Platt/Getty Images
本文首发于 , 更新于 。
Want more content like this Register for free site membership to get regular updates and your own personal content feed.
Share via
Share this Page12
Save